Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
暂无分享,去创建一个
H. Teppler | A. Rodgers | S. Nachman | L. Frenkel | R. Hazra | B. Graham | T. Fenton | R. Browning | A. Wiznia | B. Homony | C. Alvero